%0 Journal Article %A Jane E. Sinclair %A Yanshan Zhu %A Gang Xu %A Wei Ma %A Haiyan Shi %A Kun-Long Ma %A Chun-Feng Cao %A Ling-Xi Kong %A Ke-Qiang Wan %A Juan Liao %A Hai-Qiang Wang %A Matt Arentz %A Meredith Redd %A Linda A. Gallo %A Kirsty R. Short %T The role of pre-existing chronic disease in cardiac complications from SARS-CoV-2 infection: A systematic review and meta-analysis %D 2020 %R 10.1101/2020.06.21.20136622 %J medRxiv %P 2020.06.21.20136622 %X Importance SARS-CoV-2 is associated with multiple direct and indirect effects to the heart. It is not yet well defined whether patient groups at increased risk of severe respiratory disease due to SARS-CoV-2 infection also experience a heightened incidence of cardiac complications.Objective We sought to analyse the role of pre-existing chronic disease (chronic respiratory illness, cardiovascular disease (CVD), hypertension and diabetes mellitus) in the development of cardiac complications from SARS-CoV-2.Data Sources We retrospectively investigated published (including pre-prints), publicly released, de-identified, data made available between Dec 1, 2019, and May 11, 2020. Information was accessed from PubMed, Embase, medRxiv and SSRN.Study Selection 379 full-text articles were reviewed and 321 excluded for lack of original research, irrelevance to outcome, inappropriate cohort, or small patient numbers (case reports of <10 patients). Data were extracted from two studies and the remaining 56 contacted to request appropriate data, to which three responded with data contributions. A final of five studies were included.Data Extraction and Synthesis This systematic review was conducted based on PRISMA and MOOSE statements. Included studies were critically appraised using Newcastle Ottawa Quality Assessment Scale (NOS). Data were extracted independently by multiple observers. A fixed-effects model was selected for the meta-analysis based on relatively low heterogeneity between the studies (I 2<50%).Main Outcome and Measures Cardiac complications were determined via blood levels of cardiac biomarkers above the 99th percentile of the upper reference limit, abnormalities in electrocardiography, and/or abnormalities in echocardiography.Results SARS-CoV-2-infected patients who developed cardiac complications were, on average, 10 years older than those that did not. Pooled analyses showed the development of cardiac complications from SARS-CoV-2 was significantly increased in patients with underlying chronic respiratory illness (OR 2.88[1.45,5.71]), CVD (OR 5.12[3.09,8.48]), hypertension (OR 4.37[2.99,6.39]) and diabetes mellitus (OR 2.61[1.67,4.09]).Conclusions and Relevance Older age and pre-existing chronic respiratory illness, CVD, hypertension, and diabetes mellitus may represent prognostic factors for the development of additional cardiac complications in COVID-19, highlighting the need for a multidisciplinary approach to chronic disease patient management and providing justification for a larger scale observational study.Competing Interest StatementThe authors have declared no competing interest.Funding StatementKRS was supported by the Australian Research Council [DE180100512]. Collection of data contributed by Xu et al. was supported by the Guangzhou Health Research Project, the Guangzhou Health Committee (NO.20191A010014). The sponsors of this study had no role in the study design, collection, analysis, and interpretation of data, report writing, or the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human Ethics Research Office Cumbrae-Stewart Building #72 The University of Queensland St Lucia, QLD 4072 CRICOS PROVIDER NUMBER 00025B 2020001352 This project has been reviewed by the Office of Research Ethics and is deemed to be exempt from ethics review under the National Statement on Ethical Conduct in Human Research and University of Queensland policy, as research that uses only existing collections of data that contain only non-identifiable data about human beings AND is of negligible risk.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data relevant to the investigation have been included in the manuscript. Included data from Liu et al., 2020 and Shi et al., 2020 are published and publicly available. Data from remaining included studies may be obtained by contacting respective authors of each study. %U https://www.medrxiv.org/content/medrxiv/early/2020/06/23/2020.06.21.20136622.full.pdf